How do HIF inhibitors work?
Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) enzyme inhibitors are a new class of agents for the treatment of anemia in CKD. These agents work by stabilizing the HIF complex and stimulating endogenous erythropoietin production even in patients with end-stage kidney disease.
What inhibits HIF?
A second oxygen dependent hydroxylation occurs at an asparagine residue in the C-TAD of HIFα and is catalyzed by a different oxygenase, called FIH (Factor Inhibiting HIF) [29,30]. FIH downregulates HIF transcriptional activity by impairing HIF binding to CBP/p300.
What is Roxadustat?
Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD).
Is Roxadustat FDA approved?
FDA Committee Votes Against Approval of Roxadustat for Anemia of Chronic Kidney Disease. The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has decided not to recommend the approval of roxadustat for the treatment of patients with chronic kidney disease-related anemia.
Is HIF-1 a gene or a transcription factor?
heterodimeric transcription factor
HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The HIF-1α and HIF-1β proteins both contain basic helix-loop-helix motifs that bind DNA and cause subunit dimerization [7,8,9].
Is Roxadustat approved in Europe?
Roxadustat is approved in EU member states, including the EEA countries, as well as in Japan, China, Chile and South Korea for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
What effect did Roxadustat have on hepcidin concentrations in clinical trials?
Beyond elevating EPO level, roxadustat could correct anemia by handling iron metabolism and particularly by decreasing the hepcidin levels, a response that was independent of baseline CRP levels and disease states of CKD patients (not receiving dialysis, hemodialysis, or peritoneal dialysis).
What is prolyl hydroxylase inhibitor?
Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases Chronic kidney disease, cancer, chronic inflammatory disorders, nutritional, and genetic deficiency can cause anemia. Hypoxia causes induction of hypoxia-inducible factor (HIF), which stimulates erythropoietin (EPO) synthesis.
What are HIF-prolyl hydroxylases?
HIF-prolyl hydroxylases (PHs) are molecules that constitute the core molecular mechanism of detecting a decrease in the partial pressure of oxygen, or hypoxia, in the cells; they can be called oxygen sensors.
What is the role of HIF-prolyl hydroxylase inhibitors in iron metabolism?
HIF-prolyl hydroxylase inhibitors coordinate erythropoiesis with iron metabolism. Simplified overview of the role of HIF in the regulation of iron metabolism.
What is the mechanism of action of HF2 HIF2?
HIF-2 induces renal and hepatic erythropoietin (EPO) synthesis in response to hypoxia or administration of hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD) inhibitors (HIF-PHI), which stimulate erythropoiesis.